alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**
**EXHIBIT 12.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGEACT OF 1934,**

**AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, O. James Sterling, certify that: 

 
6.
I have reviewed this annual report on Form 20-F of Renalytix AI plc;

 
7.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state amaterial fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

 
8.
Based on my knowledge, the financial statements, and other financial information included in this report,fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; 

 
9.
The company’s other certifying officer and I are responsible for establishing and maintaining disclosurecontrols and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have: 

 
 a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to bedesigned under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is beingprepared; and 

 
 b.
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in thisreport our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

 
 c.
Disclosed in this report any change in the Company’s internal control over financial reporting thatoccurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and 

 
10.
The company’s other certifying officer and I have disclosed, based on our most recent evaluation ofinternal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): 

 
 a.
All significant deficiencies and material weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and 

 
 b.
Any fraud, whether or not material, that involves management or other employees who have a significant role inthe company’s internal control over financial reporting. 

 
Date: October 27, 2020  By: 
/s/ O. James Sterling
         O. James Sterling         Chief Financial Officer**
_________________________________________ 

 

 

Order Michigan Supreme Court 

Lansing, Michigan 

October 14, 2005 Clifford W. Taylor,

 Chief Justice 

128223 Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee, 

Robert P. Young, Jr. 

Stephen J. Markman,

 Justices 

v SC: 128223 

 COA: 259543 

Genesee CC: 04-014768-FC 

THEODORE HAROLD NOVAK, 

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the February 4, 2005 

order of the Court of Appeals is considered and, pursuant to MCR 7.302(G)(1), in lieu of 

granting leave to appeal, we REMAND this case to the Court of Appeals for 

consideration as on leave granted of (1) whether defendant’s use of a toy gun to commit 

the armed robbery is accounted for by the sentencing guidelines, MCL 777.31, (2) in any 

event, whether the facts of this case constitute substantial and compelling reasons to 

depart from the sentencing guidelines range, and (3) if so, whether the extent of the trial 

court’s departure was justified by those reasons. See MCL 769.34(3); People v Babcock, 

469 Mich 247 (2003). 

We do not retain jurisdiction. 

WEAVER, J., dissents and states as follows: 

I dissent from the order remanding this case to the Court of Appeals for 

consideration as on leave granted. Applying the analysis of my partial dissent and partial 

concurrence in People v Babcock, 469 Mich 247, 280-284 (2003), I would deny leave. 

The trial court satisfied the requirement for “a substantial and compelling reason” for its 

departure from the sentencing guidelines, and its decision did not venture beyond the 

range of principled outcomes under the circumstances. 

s1010 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

October 14, 2005 

Clerk
#### Hughes, *et al. v.*Spratling.

*Assumpsit.*

(Decided Jan. 9, 1912.

57 South. 629.)

1. *Seals; Sealed Instrument; L.*S. — The mere addition of tlie letters “L. S.” following the name of the signer does not make the instrument a sealed instrument without any expression in the instrument of a purpose to seal it.

2. *Bonds; Hote; Pleading; Variance.*— Where the complaint declares on a bond under seal and the proof discloses an unsealed promise to pay, there is a fatal variance.

Appeal from Macon Circuit Court.

Heard before Hon. S. L. Brewer.

Assumpsit by John Spratling against John Hughes and another. Judgment for plaintiff and defendant appeals.

Reversed and remanded.

*518O. S-. Lewis, for appellant.

The instrument introduced. in evidence was not a sealed *instrument.*— Breitling *v.*Marks, 128 Ala. 222. A bond is not a promissory *note.*— Phillips *v. Am. G-. Oo.,*110 Ala. 521. A variance is properly raised by- a request for the general charge.— *N. Y. L. I. Oo. v. McPherson,*137 Ala. 119.

H. P. Merritt, for appellee.

No brief reached the Reporter.

PELHAM, J.

The complaint declared on a bond under seal, and the writing introduced in evidence did not express or indicate in the body of the instrument a purpose to seal it, and the mere affixing of the letters “L. S.” to the names of the subscribers does not make it a writing under *seal.*—Breitling *v. Marx,*123 Ala. 222, 26 South. 203; *Blackwell v. Hamilton,*47 Ala. 470; *Carter v. Penn,*4 Ala. 140.

The defendants in the court below, appellants here, requested the general charge in writing, which was refused. There was a variance between the allegations and the proof, in that the appellee declared on a bond under seal, and the instrument introduced in evidence was not a bond under seal, but a promissory note, and the court was in error in refusing the general charge requested by *appellants.*—Phillips *v. Americus Guano Co.,*110 Ala. 521, 18 South. 104; *Breitling v. Marx, supra; Burton et al. v. Dangerfield,*141 Ala. 285, 291, 37 South. 350; *N. Y. Life Ins. Co. v. McPherson,*137 Ala. 116, 119, 33 South. 825.

For the error committed in refusing the general charge requested by appellants, the case must be reversed.

Reversed and remanded.
United States Department of Agriculture

Animal and Plant Health Inspection Service

Plant Protection and Quarantine

Administrative Action to Provide an Irradiation Dose for 

Mango Pulp Weevil 

Treatment Evaluation Document

Date: November 28, 2012

Treatments, Pests, Commodities and Countries

New Treatment/ 

Revision/Deletion 

Treatment Type Target Pests Commodity 

Applicable

Country(ies) of 

origin

New Pest Specific 

Irradiation Dose

Irradiation Mango pulp 

weevil

(Sternochetus

frigidus (Fabr.))

Mango

(Mangifera 

indica L.)

All

Objective: To provide supporting information and justification for providing an 

irradiation dose to neutralize mango pulp weevil in mangoes. Availability of this dose 

will help facilitate trade of mangoes from countries such as Philippines where this pest is 

known to occur and associated with mangoes.

Overview & Evaluation: Mango pulp weevil (Strenochetus frigidus (Fabr.) syn. 

Strenochetus gravis) is a pest of quarantine significance associated with mango fruit in 

certain Asian countries e.g. Bangladesh, India, Indonesia, Malaysia, Myanmar, 

Philippines and Singapore (Obra, 2012). In Philippines, this pest is reported to occur in 

southern part of the Palawan Island. In the absence of a specific treatment for the pest, 

countries such as India are required to treat mangoes with a generic irradiation dose of 

400 Gy to meet U.S. entry requirements. With the objective of being able to export 

mangoes from the Palawan Island of Philippines and from other parts of the country that 

might get infested with this pest in future, the Philippine Nuclear Research Institute, in 

cooperation with the U.S. Department of Agriculture (USDA), conducted an extensive 

study to find a specific irradiation dose for the mango pulp weevil and reported their 

findings to USDA’s Animal and Plant Health Inspection Service (APHIS) in 2012. 

APHIS evaluated the research and found the methodology and results to be appropriate. 

Based on the evaluation, APHIS Treatment Quality Assurance Unit recommended 
2

acceptance of 165 Gy as the minimum absorbed dose for the mango pulp weevil 

(Strenochetus frigidus) (Bailey, 2012. Pers. Comm.). 

This is consistent with APHIS’ policy published in the Federal Register in 1996 that 

whenever a lower specific dose is available for a plant pest for which a higher dose has 

been approved earlier, we would publish and make available that lower dose to meet our 

phytosanitary requirements. 

Decision: Amend the PPQ Treatment Manual to provide for a specific irradiation minimum 

absorbed dose of 165 Gy for mango pulp weevil (Strenochetus frigidus (Fabr.)).

Author:

Inder P.S. Gadh, Ph.D.

Senior Risk Manager - Treatments

USDA APHIS PPQ 

4700 River Road, unit 133

Riverdale, MD 20737

301-851-2141

Paul.gadh@aphis.usda.gov

References Cited:

Obra, G. 2012. Establishment of Radiation Dose for Quarantine Treatment of Mango 

Pulp Weevil, Sternochetus frigidus (Fabr.), in Philippine Mangoes. Philippine 

Nuclear Research Institute, Department of Science and Technology. Diliman, Quezon 

City, Philippines. 19 p.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
The  schedule  contains  summary   information   extracted  from  the  financial
statements  of the September  30, 1998 Form 10-Q of  Integrated  Resources  High
Equity Partners, Series 85 and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                       6,628,331
<SECURITIES>                                         0
<RECEIVABLES>                                   90,439
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              41,226,384
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  38,917,076 
<TOTAL-LIABILITY-AND-EQUITY>                41,226,384
<SALES>                                              0
<TOTAL-REVENUES>                             7,166,179
<CGS>                                                0
<TOTAL-COSTS>                                2,775,832
<OTHER-EXPENSES>                             2,587,600
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              2,661,314
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          2,661,314
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,661,314
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
         

</TABLE>
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 205 Introduced in House (IH)]

110th CONGRESS
  1st Session
                                H. R. 205

 To amend title XVIII of the Social Security Act to extend the annual 
 enrollment periods of the Medicare prescription drug benefit program 
               and under the Medicare Advantage program.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 4, 2007

  Mr. Saxton (for himself and Mr. Smith of New Jersey) introduced the 
following bill; which was referred to the Committee on Ways and Means, 
 and in addition to the Committee on Energy and Commerce, for a period 
    to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL

 
 To amend title XVIII of the Social Security Act to extend the annual 
 enrollment periods of the Medicare prescription drug benefit program 
               and under the Medicare Advantage program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare Prescription Drug 
Enrollment Extension Act of 2007''.

SEC. 2. EXTENSION OF ANNUAL ENROLLMENT PERIODS FOR THE MEDICARE 
              PRESCRIPTION DRUG BENEFIT PROGRAM AND MEDICARE ADVANTAGE 
              PROGRAM.

    (a) In General.--Section 1851(e)(3)(B) of the Social Security Act 
(42 U.S.C. 1395w-21(e)(3)(B)) is amended--
            (1) by striking ``and'' at the end of clause (iii); and
            (2) by striking clause (iv) and inserting the following:
                            ``(iv) with respect to 2007, the period 
                        beginning on November 15, 2006, and ending on 
                        December 31, 2006; and
                            ``(v) with respect to a succeeding year, 
                        the period beginning on November 15 of the year 
                        before such year and ending on March 31 of such 
                        year.''.
    (b) Conforming Effectiveness of Election.--Section 1851(f)(3) of 
such Act (42 U.S.C. 1395w-21(f)(3)) is amended by inserting after ``the 
following year'' the following: ``, except that in the case of an 
election made under subsection (e)(3)(B)(v) on or after January 1 of a 
year, the election shall take effect on the first day of the first 
month that begins at least 14 days after the date of such election''.
                                 <all>
```
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Leslie’s, Inc. (the “Company”) on Form 10-K for the year ending October 3, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

|   | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

 

| Date: December 23, 2020 |   | By:    | /s/ Michael R. Egeck    |
|-------------------------|--------|--------|-------------------------|
|                    |   |   | Michael R. Egeck        |
|                    |   |   | Chief Executive Officer |
|  | Mid-Atlantic Integrated Assessment             Recent Additions | Contact                     Us |                     Print                     Version                     Search:                     EPA                     Home > Mid-Atlantic Integrated                     Assessment                    > Projects                     and Reports > Maryland                     Agriculture and Your Watershed |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Maryland Agriculture and Your Watershed
United States                            Environmental Protection                            Agency

Region                             3                            Philadelphia, PA 19103

EPA/903/R-00/009                            July 2001www.epa.gov

                            
Maryland Agriculture and Your Watershed

Read online HTML VersionDownload this report as a PDF file (5.71 MB)Table of Contents

 

Maryland         Agriculture and Your Watershed:        MD Agriculture Cover Page | Credits         | Abstract | Notice | Acknowledgements         | Table of Contents | IntroductionCrops | Livestock         | Agricultural Intensity by Watershed         | Environmental Concerns | References         | Appendix: Methodology
Mid-Atlantic       Integrated AssessmentOffice of Research       & Development, U.S. EPA Region       III - Philadelphia
EPA Home | Privacy         and Security Notice |         Contact Us

 

  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
Exhibit 32.1

# CERTIFICATIONS PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of QMed, Inc. (the Company), on Form 10-Q for the quarter ended August 31, 2006, as filed with the Securities and Exchange Commission (the Report), Michael W. Cox, Chief Executive Officer of the Company and William T. Schmitt, Jr., Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

| |  | (1) |  | The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and
| |  | --- |  | ---------------------------------------------------------------------------------------------------------------------

| |  | (2) |  | The
information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
| |  | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------

/s/ Michael W. Cox
Michael W. CoxChief Executive OfficerOctober 6, 2006

/s/ William T. Schmitt, Jr.William T. Schmitt, Jr.Chief Financial OfficerOctober 6, 2006

[A signed original of this written statement required by Section 906 has been provided to QMed, Inc. and will be retained by QMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]
exv10w5



 


EXHIBIT 10.5



Second Amendment to the Equity Office Properties Trust

1997 Non-Qualified Employee Share Purchase Plan

(As Amended and Restated Effective January 1, 1998)



     WHEREAS, Equity Office Properties Trust (the “Company”) has adopted the
Equity Office Properties Trust 1997 Non-Qualified Employee Share Purchase Plan,
as amended and restated effective January 1, 1998 (the “Plan”); and


     WHEREAS, on February 16, 1999,the Company amended section 2.16 of the Plan
to change the Purchase Period; and


     WHEREAS, the Company desires to further amend the Plan to change the
Purchase Period;


     NOW, THEREFORE, the Company hereby amends the Plan, effective May 20,
2003, in the following respects:


     Section 2.16 is amended to read as follows:


“2.16 The term “Purchase Period” shall mean a period set by the
Committee. Unless changed by the Committee, commencing with the
Purchase Period which begins December 1, 2003, each Purchase
Period shall begin on the dates listed below and shall end on the
business days coinciding with or immediately preceding the dates
listed below:



	 
	March 1-May 31
	June 1-August 31
	September 1-November 30
	December 1-February 28*





                              * In the case of a leap year the fourth quarter purchase period
shall be



	 
	December 1-February 29”





     IN WITNESS WHEREOF, this Amendment has been executed by a duly authorized
officer of the Company, this 21st day of May 2003.



	 	 	 	 	 
	 	 	EQUITY OFFICE PROPERTIES TRUST
	 	 	 	 	 
	 	 	
By:
	 	/s/ Stanley M. Stevens
	 	 	 	 	

	 	 	
Name:

Title:
	 	Stanley M. Stevens

Executive Vice President, Chief Legal

Counsel and Secretary